News
- Author:
- Randy Dotinga
Publish date: November 17, 2023
Two phase 3 trials of the recently approved IV formulation of secukinumab showed its efficacy versus placebo in treating psoriatic arthritis and ax...
News
- Author:
- Randy Dotinga
Publish date: November 16, 2023
“Joyner said he’s ‘frustrated’ with the NIH’s ‘bureaucratic rope-a-dope,’ calling the agency’s guidelines ‘a wet blanket.’ ”
News
- Author:
- Randy Dotinga
Publish date: November 16, 2023
The level of risk for MACE rose with the dose, duration, and recency of GC use, and risk increased significantly at prednisone-equivalent doses as ...
News
- Author:
- Randy Dotinga
Publish date: November 14, 2023
Phase 4 trial offers insight into efficacy in patients whose mild cases have gotten less research attention.
News
- Author:
- Randy Dotinga
Publish date: November 14, 2023
Q & A with an expert on how the FDA’s Project Optimus targets toxicity and how it could spell the end of traditional dose-escalation trials.
News
- Author:
- Randy Dotinga
Publish date: November 14, 2023
A real-world analysis finds that some patients who receive reduced-dose glucocorticoids may have a higher risk of poor outcomes.
News
- Author:
- Randy Dotinga
Publish date: November 13, 2023
G-CAN hopes to standardize terminology and finally oust ‘pseudo’ vernacular.
News
- Author:
- Randy Dotinga
Publish date: November 10, 2023
Urate-lowering drugs might be OK early on; gout may boost peripheral arterial disease.
News
- Author:
- Randy Dotinga
Publish date: November 9, 2023
Trials are small and incomplete, but CAR T-cell therapy has yielded promising early results in treating T-cell blood cancers.
News
- Author:
- Randy Dotinga
Publish date: November 1, 2023
According to the lawsuit, the hospital illegally required neuropsychological and eye examinations of physicians aged 70 or older who sought to gain...
News
- Author:
- Randy Dotinga
Publish date: October 25, 2023
While it’s extremely difficult to link cancer rates to military service, rese...
News
- Author:
- Randy Dotinga
Publish date: October 23, 2023
Don’t be too quick to stop therapy or too slow to restart it, researcher tells ECTRIMS audience.
News
- Author:
- Randy Dotinga
Publish date: October 20, 2023
Nearly half of patients with coding for NMO were also listed as having MS – a very similar condition.
News
- Author:
- Randy Dotinga
Publish date: October 20, 2023
Two MS researchers disagree over how tightly they’re connected, and one says “second hit” may be factor.
News
- Author:
- Randy Dotinga
Publish date: October 18, 2023
Neurologists outline findings as the MS field works toward consensus on HSCT as rescue therapy.
